vs
Side-by-side financial comparison of Great Elm Group, Inc. (GEG) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $3.0M, roughly 1.8× Great Elm Group, Inc.). Taysha Gene Therapies, Inc. runs the higher net margin — -507.8% vs -549.6%, a 41.8% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -14.1%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -4.6%).
Great Elm Group, Inc. is an alternative asset management firm that offers private credit products, real asset investment vehicles, and customized capital solutions for small and medium-sized enterprises. It primarily serves institutional investors and high-net-worth individuals across the North American market.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
GEG vs TSHA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0M | $5.5M |
| Net Profit | $-16.5M | $-27.9M |
| Gross Margin | 99.5% | — |
| Operating Margin | -140.6% | -516.0% |
| Net Margin | -549.6% | -507.8% |
| Revenue YoY | -14.1% | 171.3% |
| Net Profit YoY | -1507.1% | -48.3% |
| EPS (diluted) | $-0.50 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0M | $5.5M | ||
| Q3 25 | $10.8M | $0 | ||
| Q2 25 | — | $2.0M | ||
| Q1 25 | $3.2M | $2.3M | ||
| Q4 24 | $3.5M | $2.0M | ||
| Q3 24 | $4.0M | $1.8M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | $2.8M | $3.4M |
| Q4 25 | $-16.5M | $-27.9M | ||
| Q3 25 | $-7.9M | $-32.7M | ||
| Q2 25 | — | $-26.9M | ||
| Q1 25 | $-4.5M | $-21.5M | ||
| Q4 24 | $1.2M | $-18.8M | ||
| Q3 24 | $2.6M | $-25.5M | ||
| Q2 24 | — | $-20.9M | ||
| Q1 24 | $-3.1M | $-24.1M |
| Q4 25 | 99.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 86.9% | — | ||
| Q3 24 | 84.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -140.6% | -516.0% | ||
| Q3 25 | -34.5% | — | ||
| Q2 25 | — | -1347.1% | ||
| Q1 25 | -79.6% | -930.5% | ||
| Q4 24 | -56.4% | -985.8% | ||
| Q3 24 | -50.0% | -1448.4% | ||
| Q2 24 | — | -1915.4% | ||
| Q1 24 | -67.1% | -713.3% |
| Q4 25 | -549.6% | -507.8% | ||
| Q3 25 | -73.3% | — | ||
| Q2 25 | — | -1353.6% | ||
| Q1 25 | -140.1% | -935.2% | ||
| Q4 24 | 33.5% | -929.0% | ||
| Q3 24 | 66.1% | -1427.5% | ||
| Q2 24 | — | -1882.0% | ||
| Q1 24 | -111.2% | -705.4% |
| Q4 25 | $-0.50 | $-0.08 | ||
| Q3 25 | $-0.24 | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | $-0.17 | $-0.08 | ||
| Q4 24 | $0.04 | $-0.07 | ||
| Q3 24 | $0.08 | $-0.10 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | $-0.10 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $51.2M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $55.8M | $246.9M |
| Total Assets | $135.5M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $51.2M | $319.8M | ||
| Q3 25 | $53.5M | $297.3M | ||
| Q2 25 | — | $312.8M | ||
| Q1 25 | $31.5M | $116.6M | ||
| Q4 24 | $44.3M | $139.0M | ||
| Q3 24 | $44.1M | $157.7M | ||
| Q2 24 | — | $172.7M | ||
| Q1 24 | $44.1M | $124.0M |
| Q4 25 | $55.8M | $246.9M | ||
| Q3 25 | $73.8M | $219.0M | ||
| Q2 25 | — | $248.7M | ||
| Q1 25 | $57.2M | $55.1M | ||
| Q4 24 | $62.3M | $71.5M | ||
| Q3 24 | $63.9M | $88.8M | ||
| Q2 24 | — | $108.9M | ||
| Q1 24 | $65.0M | $53.8M |
| Q4 25 | $135.5M | $343.3M | ||
| Q3 25 | $155.0M | $316.6M | ||
| Q2 25 | — | $333.3M | ||
| Q1 25 | $137.2M | $138.4M | ||
| Q4 24 | $138.5M | $160.4M | ||
| Q3 24 | $137.3M | $180.2M | ||
| Q2 24 | — | $200.4M | ||
| Q1 24 | $148.4M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.9M | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.9M | $-26.7M | ||
| Q3 25 | $3.8M | $-24.2M | ||
| Q2 25 | — | $-20.2M | ||
| Q1 25 | $-1.3M | $-22.0M | ||
| Q4 24 | $-4.0M | $-18.3M | ||
| Q3 24 | $-5.8M | $-21.6M | ||
| Q2 24 | — | $-21.5M | ||
| Q1 24 | $1.4M | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.44× | — | ||
| Q3 24 | -2.19× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GEG
| Management Service Base | $1.8M | 60% |
| Other | $1.2M | 40% |
TSHA
Segment breakdown not available.
